CSPC Pharmaceutical Group (1093.HK) Receives Clinical Trial Approval for SYH2061 Injection

Bulletin Express

Oct 24

CSPC Pharmaceutical Group Limited (the “Group”) announced that its independently developed SYH2061 Injection, a double-stranded small interfering RNA (siRNA) drug, has obtained clinical trial approval in China from the National Medical Products Administration. The product, a Class 1 new chemical drug, uses N-acetylgalactosamine (GalNAc) conjugation for liver-targeted delivery and reduces complement component C5 levels through subcutaneous administration.

According to the announcement, the product delivers a sustained gene-silencing effect and represents the first locally developed ultra-long-lasting siRNA drug targeting C5 to enter clinical trials in China. It is intended for the treatment of IgA nephropathy and other complement-mediated diseases. Preclinical studies demonstrated strong pharmacological activity, long-lasting therapeutic effects, and a favorable safety profile, suggesting significant potential for clinical development value.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1161220282"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161220282\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161220282?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 18:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161220282","market":"hk","top_or_hot":-1,"title":"CSPC Pharmaceutical Group (1093.HK) Receives Clinical Trial Approval for SYH2061 Injection","media":"Bulletin Express","content":"<p>CSPC Pharmaceutical Group Limited (the “Group”) announced that its independently developed SYH2061 Injection, a double-stranded small interfering RNA (siRNA) drug, has obtained clinical trial approval in China from the National Medical Products Administration. The product, a Class 1 new chemical drug, uses N-acetylgalactosamine (GalNAc) conjugation for liver-targeted delivery and reduces complement component C5 levels through subcutaneous administration.</p>\n<p>According to the announcement, the product delivers a sustained gene-silencing effect and represents the first locally developed ultra-long-lasting siRNA drug targeting C5 to enter clinical trials in China. It is intended for the treatment of IgA nephropathy and other complement-mediated diseases. Preclinical studies demonstrated strong pharmacological activity, long-lasting therapeutic effects, and a favorable safety profile, suggesting significant potential for clinical development value.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharmaceutical Group (1093.HK) Receives Clinical Trial Approval for SYH2061 Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharmaceutical Group (1093.HK) Receives Clinical Trial Approval for SYH2061 Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-24 18:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (the “Group”) announced that its independently developed SYH2061 Injection, a double-stranded small interfering RNA (siRNA) drug, has obtained clinical trial approval in China from the National Medical Products Administration. The product, a Class 1 new chemical drug, uses N-acetylgalactosamine (GalNAc) conjugation for liver-targeted delivery and reduces complement component C5 levels through subcutaneous administration.</p>\n<p>According to the announcement, the product delivers a sustained gene-silencing effect and represents the first locally developed ultra-long-lasting siRNA drug targeting C5 to enter clinical trials in China. It is intended for the treatment of IgA nephropathy and other complement-mediated diseases. Preclinical studies demonstrated strong pharmacological activity, long-lasting therapeutic effects, and a favorable safety profile, suggesting significant potential for clinical development value.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1161220282","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161220282","pubTimestamp":1761300645,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CSPC Pharmaceutical Group Limited (the “Group”) announced that its independently developed SYH2061 Injection, a double-stranded small interfering RNA (siRNA) drug, has obtained clinical trial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团（1093.HK）SYH2061注射液获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Limited (the “Group”) announced that its independently developed SYH2061 Injection, a double-stranded small interfering RNA (siRNA) drug, has obtained clinical trial approval in China from the National Medical Products Administration. The product, a Class 1 new chemical drug, uses N-acetylgalactosamine (GalNAc) conjugation for liver-targeted delivery and reduces complement component C5 levels through subcutaneous administration.\nAccording to the announcement, the product delivers a sustained gene-silencing effect and represents the first locally developed ultra-long-lasting siRNA drug targeting C5 to enter clinical trials in China. It is intended for the treatment of IgA nephropathy and other complement-mediated diseases. Preclinical studies demonstrated strong pharmacological activity, long-lasting therapeutic effects, and a favorable safety profile, suggesting significant potential for clinical development value.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}